0.5988

3.48% -0.0216

After Hours: .59 -0.0088 -1.47%

Cytomx Therapeutics Inc (CTMX)

Overview News Price History Option Chain Financials Discussions Forecast

Cytomx Therapeutics Inc stock is traded at $0.5988, with a volume of 2.40M. It is down -3.48% in the last 24 hours and down -24.63% over the past month. CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Previous Close:

$0.6204

Open:

$0.61

24h Volume:

2.40M

Relative Volume:

1.35

Market Cap:

$47.96M

Revenue:

$101.21M

Net Income/Loss:

$-569.00K

P/E Ratio:

-29.94

EPS:

-0.02

Net Cash Flow:

$-56.88M

1W Performance:

-2.67%

1M Performance:

-24.63%

6M Performance:

-52.10%

1Y Performance:

-72.15%

1-Day Range:

$0.57

$0.624

1-Week Range:

$0.57

$0.777

52-Week Range:

$0.57

$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name

Cytomx Therapeutics Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

650.515.3185

Address

151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Employee

121

Twitter

@cytomxinc

Next Earnings Date

2024-11-07

Latest SEC Filings

CTMX's Discussions on Twitter

Compare CTMX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTMX Cytomx Therapeutics Inc	0.5988	47.96M	101.21M	-569.00K	-56.88M	-0.02
VRTX Vertex Pharmaceuticals Inc	495.42	127.22B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	689.50	75.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.45	35.94B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.43	31.38B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.84	26.84B	3.32B	-860.46M	-1.04B	-8.32

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-24	Upgrade	Piper Sandler	Neutral → Overweight
May-09-24	Upgrade	Wedbush	Neutral → Outperform
May-06-24	Upgrade	Jefferies	Hold → Buy
Apr-22-24	Upgrade	JP Morgan	Underweight → Neutral
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-07-22	Downgrade	Jefferies	Buy → Hold
Jul-07-22	Downgrade	Mizuho	Buy → Neutral
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Jan-18-22	Upgrade	Barclays	Underweight → Overweight
Nov-15-21	Initiated	BTIG Research	Buy
May-28-21	Downgrade	Barclays	Equal Weight → Underweight
Mar-29-21	Initiated	JP Morgan	Overweight
Mar-23-21	Upgrade	Jefferies	Hold → Buy
Sep-22-20	Downgrade	Guggenheim	Buy → Neutral
Jun-01-20	Downgrade	Jefferies	Buy → Hold
May-14-20	Reiterated	H.C. Wainwright	Buy
Mar-24-20	Upgrade	Wedbush	Neutral → Outperform
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-20-19	Initiated	Guggenheim	Buy
Nov-11-19	Downgrade	Wedbush	Outperform → Neutral
Jun-13-19	Initiated	Mizuho	Buy
May-14-19	Initiated	Cantor Fitzgerald	Overweight
Mar-11-19	Initiated	Barclays	Overweight
Nov-26-18	Initiated	Piper Jaffray	Overweight
Oct-15-18	Initiated	Goldman	Neutral
Sep-13-18	Initiated	H.C. Wainwright	Buy
Jun-01-18	Initiated	SunTrust	Buy
Jan-05-18	Initiated	Citigroup	Buy
Sep-08-17	Initiated	Wedbush	Outperform
Mar-27-17	Initiated	H.C. Wainwright	Buy
Mar-02-17	Initiated	Instinet	Buy
Jan-03-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-02-15	Initiated	Oppenheimer	Outperform

View All

Cytomx Therapeutics Inc Stock (CTMX) Latest News

Mar 12, 2025

CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India

Mar 12, 2025

CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India

Mar 12, 2025

Mar 11, 2025

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025

CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World

Mar 11, 2025

Mar 10, 2025

What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - Stocks Register

Mar 10, 2025

CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World

Mar 10, 2025

Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue - Investing.com India

Mar 10, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages - Armenian Reporter

Mar 10, 2025

CytomX Therapeutics’ (CTMX) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Mar 10, 2025

Mar 08, 2025

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025

CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 08, 2025

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World

Mar 08, 2025

CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - TipRanks

Mar 08, 2025

Mar 07, 2025

CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

Mar 07, 2025